A pharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity and sexual health – VIVUS, Inc. (Nasdaq: VVUS) – has recently announced positive results from a Phase 2 clinical trial of Qnexa™ (formerly VI-0521).
The said clinical data has been presented at the recent North American Association for the Study of Obesity (NAASO) 2006 Annual Scientific Meeting.
Qnexa™ is an investigational oral treatment for obesity.
According to Leland Wilson, president and chief executive officer of VIVUS:
Find more details from the press release at VIVUS, Inc."Qnexa demonstrated significant weight loss and reduction in waist circumference in this study, coupled with excellent tolerability and a positive impact on certain factors pertaining to metabolic syndrome in obese patients.
This is the first time the Qnexa Phase 2 data has been presented in a medical forum and represents the beginning of our education process with practicing physicians on the potential of Qnexa."
Comment Preview